Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Open Access

Chemotherapy-Free Survival of CDK4/6 Inhibitor Combination Therapy or Endocrine Monotherapy as First-Line Treatment for HR+/HER2–Advanced Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

SKSayaka KubaMHManuel Espeso de HaroYKYusuke Kajimoto

Discussion

Loading...

Member takes

Overview

Observational study compares chemotherapy-free survival in HR+/HER2– breast cancer, revealing no significant differences in treatments.

Key Points

  • Median chemotherapy-free survival for endocrine monotherapy was 35 months compared to 30 months for the CDK4/6 inhibitor group.
  • Among 443 patients, the CDK4/6 inhibitors did not show noninferiority in chemotherapy-free survival compared to endocrine monotherapy.
  • The study utilized inverse probability of treatment weighting to adjust for patient background factors.
  • The findings highlight the need for further exploration of treatment efficacy in HR+/HER2– advanced breast cancer.

Cite This Study

Kuba et al. (2025) studied this question.

synapsesocial.com/papers/68c239a3b210217d6477d541https://doi.org/10.21203/rs.3.rs-7266744/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis2025
  2. 2Comparative long-term outcomes of first-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis2025 · 4 citations
  3. 3Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer2025
  4. 4Real-World Predictors of Survival in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: The Significance of ER Expression Level and Treatment Naivety2025
  5. 5Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer2025